A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: Results of the Optimizing anti-Platelet Therapy in diabetes MellitUS (OPTIMUS)-3 Trial

European Heart Journal

Volumn 32, Issue 7, 2011, Pages 838-846

  Angiolillo, Dominick J ^a   Badimon, Juan Jose ^b   Saucedo, Jorge F ^c   Frelinger, Andrew L ^d   Michelson, Alan D ^d   Jakubowski, Joseph A ^e   Zhu, Baojin ^f   Ojeh, Clement K ^f   Baker, Brian A ^g   Effron, Mark B ^f  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e ELI LILLY AND COMPANY   (United States)

^f Lilly USA   (United States)

^g DAIICHI SANKYO INC   (United States)

Author keywords

Coronary disease; Diabetes mellitus; Platelets

Indexed keywords

CLOPIDOGREL; PHOSPHOPROTEIN; PRASUGREL;

ADULT; ARTICLE; BLEEDING; CLINICAL ARTICLE; CONTUSION; CORONARY ARTERY DISEASE; CROSSOVER PROCEDURE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; ELECTROLYTE DISTURBANCE; EPISTAXIS; FEMALE; HEMATOCRIT; HUMAN; HUMAN CELL; LIMB PAIN; LOADING DRUG DOSE; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SIDE EFFECT; SINUSITIS; THROMBOCYTE FUNCTION; UPPER RESPIRATORY TRACT CONGESTION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VASODILATATION; VOMITING;

ADOLESCENT; ADULT; AGED; ASPIRIN; CORONARY ARTERY DISEASE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; THIOPHENES; TICLOPIDINE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79952149001     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehq494     Document Type: Article

References (23)

1. Angiolillo DJ. Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions. Diabetes Care 2009;32:531-540.
2. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Sabate M, Jimenez-Quevedo P, Hernandez R, Moreno R, Escaned J, Alfonso F, Banuelos C, Costa MA, Bass TA, Macaya C. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005;54:2430-2435. (Pubitemid 41134272)
3. Angiolillo DJ, Bernardo E, Ramirez C, Costa MA, Sabate M, Jimenez-Quevedo P, Hernandez R, Moreno R, Escaned J, Alfonso F, Banuelos C, Bass TA, Macaya C, Fernandez-Ortiz A. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol 2006;48:298-304. (Pubitemid 44026661)
4. Ferreira IA, Mocking AI, Feijge MA, Gorter G, van Haeften TW, Heemskerk JW, Akkerman JW. Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 2006;26:417-422. (Pubitemid 43732209)
5. Angiolillo DJ, Shoemaker SB, Desai B, Yuan H, Charlton RK, Bernardo E, Zenni MM, Guzman LA, Bass TA, Costa MA. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 2007;115:708-716. (Pubitemid 46294761)
6. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM. TRITON TIMI. Prasugrel vs. clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-2015. (Pubitemid 350106708)
7. Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verheugt FW, Goodman SG, Corbalan R, Purdy DA, Murphy SA, McCabe CH, Antman EM. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel- Thrombolysis in Myocardial Infarction 38. Circulation 2008;118:1626-1636.
8. Erlinge D, Varenhorst C, Brauno Ö, James S, Winters KJ, Jakubowski JA, Brandt JT, Siegbahn A, Wallentin L. Patients with poor responsiveness to thienopyridine treatment and those with diabetes have lower levels of circulating active metabolites but their platelets respond normally to the active metabolite added ex-vivo. J Am Coll Cardiol 2008;52:1968-1977.
9. Wilson SR, Antman EM, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, Angiolillo DJ, Miller DL, Luo J, McCabe CH, Braunwald E, Wiviott SD. Assessment of platelet function in diabetes mellitus: observations from the PRINCIPLE-TIMI 44 trial. Circulation 2009;120:S548-S549.
10. Jakubowski JA, Payne CD, Li YG, Brandt JT, Small DS, Farid NA, Salazar DE, Winters KJ. The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration. Thromb Haemost 2008;99:409-415. (Pubitemid 351230973)
11. Angiolillo DJ, Costa MA, Shoemaker SB, Desai B, Bernardo E, Suzuki Y, Charlton RK, Zenni MM, Guzman LA, Bass TA. Functional effects of high clopidogrel maintenance dosing in patients with inadequate platelet inhibition on standard dose treatment. Am J Cardiol 2008;101:440-445. (Pubitemid 351210628)
12. Hochholzer W, Trenk D, Frundi D, Blanke P, Fischer B, Andris K, Bestehorn HP, Buttner HJ, Neumann FJ. Time dependence of platelet inhibition after a 600 mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 2005;111:2560-2564. (Pubitemid 40740853)
13. Montalescot G, Sideris G, Meuleman C, Bal-dit-Sollier C, Lellouche N, Steg PG, Slama M, Milleron O, Collet JP, Henry P, Beygui F, Drouet L. ALBION Trial Investigators. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) Trial. J Am Coll Cardiol 2006;48:931-938. (Pubitemid 44292463)
14. Price MJ, Endemann S, Gollapudi RR, Valencia R, Stinis CT, Levisay JP, Ernst A, Sawhney NS, Schatz RA, Teirstein PS. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008;29:992-1000. (Pubitemid 351844676)
15. Weerakkody GJ, Brandt JT, Payne CD, Jakubowski JA, Naganuma H, Winters KJ. Clopidogrel poor responders: an objective definition based on Bayesian classifi- cation. Platelets 2007;18:428-435. (Pubitemid 47347052)
16. Bonello L, Camoin-Jau L, Arques S, Boyer C, Panagides D, Wittenberg O, Simeoni MC, Barragan P, Dignat-George F, Paganelli F. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 2008;51:1404-1411. (Pubitemid 351447314)
17. Varenhorst C, James S, Erlinge D, Braun OÖ, Brandt JT, Winters KJ, Jakubowski JA, Olofsson S, Wallentin L, Siegbahn A. Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin. Am Heart J 2009;157:562.e1-562.e9.
18. Angiolillo DJ, Ueno M, Goto S. Basic principles and platelet biology and clinical implications. Circ J 2010;74:597-607.
19. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, Costa MA. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 2007;49: 1505-1516. (Pubitemid 46517957)
20. Angiolillo DJ, Capranzano P, Goto S, Aslam M, Desai B, Charlton RK, Suzuki Y, Box LC, Shoemaker SB, Zenni MM, Guzman LA, Bass TA. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. Eur Heart J 2008;29:2202-2211.
21. Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, Angiolillo DJ, Hod H, Montalescot G, Miller DL, Jakubowski JA, Cairns R, Murphy SA, McCabe CH, Antman EM, Braunwald E. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 Trial. Circulation 2007;116:2923-2932. (Pubitemid 350291199)
22. Ho PM, Peterson ED, Wang L, Magid DJ, Fihn SD, Larsen GC, Jesse RA, Rumsfeld JS. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA 2008;299:532-539. (Pubitemid 351222546)
23. Sibbing D, Stegherr J, Braun S, Mehilli J, Schulz S, Seyfarth M, Kastrati A, von Beckerath N, Schomig A. A double-blind, randomized study on prevention and existence of a rebound phenomenon of platelets after cessation of clopidogrel treatment. J Am Coll Cardiol 2010;55:558-565.